The application of in silico drug-likeness predictions in pharmaceutical research.

The concept of drug-likeness, established from the analyses of the physiochemical properties or/and structural features of existing small organic drugs or/and drug candidates, has been widely used to filter out compounds with undesirable properties, especially poor ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles. Here, we summarize various approaches for drug-likeness evaluations, including simple rules/filters based on molecular properties/structures and quantitative prediction models based on sophisticated machine learning methods, and provide a comprehensive review of recent advances in this field. Moreover, the strengths and weaknesses of these approaches are briefly outlined. Finally, the drug-likeness analyses of natural products and traditional Chinese medicines (TCM) are discussed.

[1]  Tingjun Hou,et al.  Drug and Drug Candidate Building Block Analysis , 2010, J. Chem. Inf. Model..

[2]  A. Ghose,et al.  A knowledge-based approach in designing combinatorial or medicinal chemistry libraries for drug discovery. 1. A qualitative and quantitative characterization of known drug databases. , 1999, Journal of combinatorial chemistry.

[3]  Corinna Cortes,et al.  Support-Vector Networks , 1995, Machine Learning.

[4]  Ian A. Watson,et al.  Chemical fragments as foundations for understanding target space and activity prediction. , 2008, Journal of medicinal chemistry.

[5]  I. Muegge.  Selection criteria for drug‐like compounds , 2003, Medicinal research reviews.

[6]  Jens Sadowski,et al.  Optimization of the drug-likeness of chemical libraries , 2000 .

[7]  Gunnar Rätsch,et al.  Classifying 'Drug-likeness' with Kernel-Based Learning Methods , 2005, J. Chem. Inf. Model..

[8]  D. Normile.  The New Face of Traditional Chinese Medicine , 2003, Science.

[9]  J. Wang,et al.  Toward designing drug-like libraries: a novel computational approach for prediction of drug feasibility of compounds. , 1999, Journal of combinatorial chemistry.

[10]  G. Bemis,et al.  The properties of known drugs. 1. Molecular frameworks. , 1996, Journal of medicinal chemistry.

[11]  Alexander Hillisch,et al.  Improving the hit-to-lead process: data-driven assessment of drug-like and lead-like screening hits. , 2006, Drug discovery today.

[12]  W. L. Jorgensen.  The Many Roles of Computation in Drug Discovery , 2004, Science.

[13]  Markus Wagener,et al.  Potential Drugs and Nondrugs: Prediction and Identification of Important Structural Features , 2000, J. Chem. Inf. Comput. Sci..

[14]  Walters Wp,et al.  Guiding molecules towards drug-likeness. , 2002 .

[15]  W Patrick Walters,et al.  Prediction of 'drug-likeness'. , 2002, Advanced drug delivery reviews.

[16]  Igor V. Pletnev,et al.  Drug Discovery Using Support Vector Machines. The Case Studies of Drug-likeness, Agrochemical-likeness, and Enzyme Inhibition Predictions , 2003, J. Chem. Inf. Comput. Sci..

[17]  T Mitchell,et al.  Design strategies for building drug-like chemical libraries. , 2001, Current opinion in drug discovery & development.

[18]  Tingjun Hou,et al.  A 3D Structure Database of Components from Chinese Traditional Medicinal Herbs , 2002, J. Chem. Inf. Comput. Sci..

[19]  Lei Chen,et al.  Drug-likeness analysis of traditional Chinese medicines: 2. Characterization of scaffold architectures for drug-like compounds, non-drug-like compounds, and natural compounds from traditional Chinese medicines , 2013, Journal of Cheminformatics.

[20]  Darren V. S. Green,et al.  Selecting Combinatorial Libraries to Optimize Diversity and Physical Properties , 1999, J. Chem. Inf. Comput. Sci..

[21]  Yutaka Endo,et al.  Development of a Method for Evaluating Drug-Likeness and Ease of Synthesis Using a Data Set in Which Compounds Are Assigned Scores Based on Chemists' Intuition , 2003, J. Chem. Inf. Comput. Sci..

[22]  Ajay,et al.  Designing libraries with CNS activity. , 1999, Journal of medicinal chemistry.

[23]  Michal Vieth,et al.  Drugs in other drugs: a new look at drugs as fragments. , 2007, Drug discovery today.

[24]  Iskander Yusof,et al.  Considering the impact drug-like properties have on the chance of success. , 2013, Drug discovery today.

[25]  Wei Zhang,et al.  Recent advances in computational prediction of drug absorption and permeability in drug discovery. , 2006, Current medicinal chemistry.

[26]  Jing Lin,et al.  The role of absorption, distribution, metabolism, excretion and toxicity in drug discovery. , 2003, Current topics in medicinal chemistry.

[27]  Thomas Henkel,et al.  Statistical Investigation into the Structural Complementarity of Natural Products and Synthetic Compounds. , 1999, Angewandte Chemie.

[28]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings , 1997 .

[29]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 7. Prediction of Oral Absorption by Correlation and Classification , 2007, J. Chem. Inf. Model..

[30]  A. Hopkins,et al.  Navigating chemical space for biology and medicine , 2004, Nature.

[31]  Tingjun Hou,et al.  Recent development and application of virtual screening in drug discovery: an overview. , 2004, Current pharmaceutical design.

[32]  Matthew A Cooper,et al.  Drug-likeness and increased hydrophobicity of commercially available compound libraries for drug screening. , 2012, Current topics in medicinal chemistry.

[33]  Arup K. Ghose,et al.  Knowledge-Based, Central Nervous System (CNS) Lead Selection and Lead Optimization for CNS Drug Discovery , 2011, ACS chemical neuroscience.

[34]  David J Newman,et al.  Natural products as sources of new drugs over the period 1981-2002. , 2003, Journal of natural products.

[35]  Alessandro Pedretti,et al.  Assessing drug-likeness--what are we missing? , 2008, Drug discovery today.

[36]  Gang Chen,et al.  A New Rapid and Effective Chemistry Space Filter in Recognizing a Druglike Database , 2005, J. Chem. Inf. Model..

[37]  C. Dobson.  Chemical space and biology , 2004, Nature.

[38]  Ricardo Macarrón,et al.  Yin and Yang in medicinal chemistry: what does drug-likeness mean? , 2011, Future medicinal chemistry.

[39]  Hans-Joachim Böhm,et al.  A guide to drug discovery: Hit and lead generation: beyond high-throughput screening , 2003, Nature Reviews Drug Discovery.

[40]  Robert Bywater,et al.  Improving the Odds in Discriminating "Drug-like" from "Non Drug-like" Compounds , 2000, J. Chem. Inf. Comput. Sci..

[41]  Gisbert Schneider,et al.  Scaffold diversity of natural products: inspiration for combinatorial library design. , 2008, Natural product reports.

[42]  Lawrence.  Rediscovering natural product biodiversity. , 1999, Drug discovery today.

[43]  H. Kubinyi,et al.  A scoring scheme for discriminating between drugs and nondrugs. , 1998, Journal of medicinal chemistry.

[44]  Qian Li,et al.  Drug-likeness analysis of traditional Chinese medicines: 1. property distributions of drug-like compounds, non-drug-like compounds and natural compounds from traditional Chinese medicines , 2012, Journal of Cheminformatics.

[45]  Jens Sadowski,et al.  Comparison of Support Vector Machine and Artificial Neural Network Systems for Drug/Nondrug Classification , 2003, J. Chem. Inf. Comput. Sci..

[46]  X. Lewell,et al.  Drug-motif-based diverse monomer selection: method and application in combinatorial chemistry. , 1997, Journal of molecular graphics & modelling.

[47]  H. Kubinyi.  Drug research: myths, hype and reality , 2003, Nature Reviews Drug Discovery.

[48]  G. V. Paolini,et al.  Quantifying the chemical beauty of drugs. , 2012, Nature chemistry.

[49]  Bruno Boulanger,et al.  Towards a new age of virtual ADME/TOX and multidimensional drug discovery , 2002, J. Comput. Aided Mol. Des..

[50]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[51]  Michael S Lajiness,et al.  Molecular properties that influence oral drug-like behavior. , 2004, Current opinion in drug discovery & development.

[52]  P. Leeson,et al.  A comparison of physiochemical property profiles of development and marketed oral drugs. , 2003, Journal of medicinal chemistry.

[53]  Tudor I. Oprea,et al.  Understanding drug‐likeness , 2011 .

[54]  Andreas Bender,et al.  A Large Descriptor Set and a Probabilistic Kernel-Based Classifier Significantly Improve Druglikeness Classification , 2007, J. Chem. Inf. Model..

[55]  Jonathan J. Darrow,et al.  Drug development and FDA approval, 1938-2013. , 2014, The New England journal of medicine.

[56]  I. Muegge,et al.  Simple selection criteria for drug-like chemical matter. , 2001, Journal of medicinal chemistry.

[57]  Michael M. Hann,et al.  RECAP-Retrosynthetic Combinatorial Analysis Procedure: A Powerful New Technique for Identifying Privileged Molecular Fragments with Useful Applications in Combinatorial Chemistry , 1998, J. Chem. Inf. Comput. Sci..

[58]  I. Kola,et al.  Can the pharmaceutical industry reduce attrition rates? , 2004, Nature Reviews Drug Discovery.

[59]  Tingjun Hou,et al.  Drug-likeness analysis of traditional Chinese medicines: prediction of drug-likeness using machine learning approaches. , 2012, Molecular pharmaceutics.

[60]  Simon J F Macdonald,et al.  How drug-like are 'ugly' drugs: do drug-likeness metrics predict ADME behaviour in humans? , 2014, Drug discovery today.

[61]  Bernd Beck,et al.  Descriptors, physical properties, and drug-likeness. , 2002, Journal of medicinal chemistry.

[62]  Peter J. Fleming,et al.  Combinatorial Library Design Using a Multiobjective Genetic Algorithm , 2002, J. Chem. Inf. Comput. Sci..

[63]  C. Lipinski.  Lead- and drug-like compounds: the rule-of-five revolution. , 2004, Drug discovery today. Technologies.

[64]  Ajay,et al.  Can we learn to distinguish between "drug-like" and "nondrug-like" molecules? , 1998, Journal of medicinal chemistry.

[65]  W Patrick Walters,et al.  Going further than Lipinski's rule in drug design , 2012, Expert opinion on drug discovery.

[66]  Sanjivanjit K. Bhal,et al.  The Rule of Five revisited: applying log D in place of log P in drug-likeness filters. , 2007, Molecular pharmaceutics.

[67]  György M. Keserü,et al.  The influence of lead discovery strategies on the properties of drug candidates , 2009, Nature Reviews Drug Discovery.

[68]  P. Leeson,et al.  The influence of drug-like concepts on decision-making in medicinal chemistry , 2007, Nature Reviews Drug Discovery.

[69]  Michal Vieth,et al.  Dependence of molecular properties on proteomic family for marketed oral drugs. , 2006, Journal of medicinal chemistry.

[70]  Tingjun Hou,et al.  ADME Evaluation in Drug Discovery, 6. Can Oral Bioavailability in Humans Be Effectively Predicted by Simple Molecular Property-Based Rules? , 2007, J. Chem. Inf. Model..

[71]  D. Newman,et al.  Natural products as sources of new drugs over the last 25 years. , 2007, Journal of natural products.

[72]  Mark A. Murcko,et al.  Virtual screening : an overview , 1998 .

[73]  Peter Kirkpatrick,et al.  Medicinal Chemistry: Shades of chemical beauty , 2012, Nature Reviews Drug Discovery.

[74]  Craig M. Crews,et al.  Molecular Understanding and Modern Application of Traditional Medicines: Triumphs and Trials , 2007, Cell.

[75]  Douglas M. Hawkins,et al.  Using Recursive Partitioning to Analyze a Large Sar Data Set , 1998 .

[76]  Tudor I. Oprea,et al.  Property distribution of drug-related chemical databases* , 2000, J. Comput. Aided Mol. Des..

[77]  Andrew C. Good,et al.  Measuring CAMD Technique Performance, 2. How "Druglike" Are Drugs? Implications of Random Test Set Selection Exemplified Using Druglikeness Classification Models , 2007, J. Chem. Inf. Model..

[78]  Michael C. Hutter,et al.  Gradual in Silico Filtering for Druglike Substances , 2008, J. Chem. Inf. Model..

[79]  G. Bemis,et al.  Properties of known drugs. 2. Side chains. , 1999, Journal of medicinal chemistry.

[80]  W. Patrick Walters,et al.  A guide to drug discovery: Designing screens: how to make your hits a hit , 2003, Nature Reviews Drug Discovery.

[81]  G. Schneider,et al.  Scaffold architecture and pharmacophoric properties of natural products and trade drugs: application in the design of natural product-based combinatorial libraries. , 2001, Journal of combinatorial chemistry.

[82]  Tudor I. Oprea,et al.  Pursuing the leadlikeness concept in pharmaceutical research. , 2004, Current opinion in chemical biology.

[83]  Li Di,et al.  Pharmaceutical profiling in drug discovery. , 2003, Drug discovery today.

[84]  Pickett,et al.  Computational methods for the prediction of 'drug-likeness' , 2000, Drug discovery today.

[85]  Stefan Wetzel,et al.  Natural-product-derived fragments for fragment-based ligand discovery , 2012, Nature Chemistry.

[86]  John Bradshaw,et al.  Identification of Biological Activity Profiles Using Substructural Analysis and Genetic Algorithms , 1998, J. Chem. Inf. Comput. Sci..

[87]  David J Newman,et al.  Natural products as sources of new drugs over the 30 years from 1981 to 2010. , 2012, Journal of natural products.

[88]  Miklos Feher,et al.  Property Distributions: Differences between Drugs, Natural Products, and Molecules from Combinatorial Chemistry , 2003, J. Chem. Inf. Comput. Sci..

[89]  J. Proudfoot,et al.  The evolution of synthetic oral drug properties. , 2005, Bioorganic & medicinal chemistry letters.

[90]  Jin-Ling Tang,et al.  Traditional Chinese medicine , 2008, The Lancet.